202 related articles for article (PubMed ID: 37340065)
1. A validated prognostic nomogram for patients with H3 K27M-mutant diffuse midline glioma.
Peng Y; Ren Y; Huang B; Tang J; Jv Y; Mao Q; Liu Y; Lei Y; Zhang Y
Sci Rep; 2023 Jun; 13(1):9970. PubMed ID: 37340065
[TBL] [Abstract][Full Text] [Related]
2. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
Castel D; Philippe C; Kergrohen T; Sill M; Merlevede J; Barret E; Puget S; Sainte-Rose C; Kramm CM; Jones C; Varlet P; Pfister SM; Grill J; Jones DTW; Debily MA
Acta Neuropathol Commun; 2018 Nov; 6(1):117. PubMed ID: 30396367
[TBL] [Abstract][Full Text] [Related]
3. Deep Learning for Noninvasive Assessment of H3 K27M Mutation Status in Diffuse Midline Gliomas Using MR Imaging.
Li J; Zhang P; Qu L; Sun T; Duan Y; Wu M; Weng J; Li Z; Gong X; Liu X; Wang Y; Jia W; Su X; Yue Q; Li J; Zhang Z; Barkhof F; Huang RY; Chang K; Sair H; Ye C; Zhang L; Zhuo Z; Liu Y
J Magn Reson Imaging; 2023 Sep; 58(3):850-861. PubMed ID: 36692205
[TBL] [Abstract][Full Text] [Related]
4. Genomic profiling and prognostic factors of H3 K27M-mutant spinal cord diffuse glioma.
Chai RC; Yan H; An SY; Pang B; Chen HY; Mu QH; Zhang KN; Zhang YW; Liu YQ; Liu X; Zhao Z; Jiang T; Wang YZ; Jia WQ
Brain Pathol; 2023 Jul; 33(4):e13153. PubMed ID: 36751054
[TBL] [Abstract][Full Text] [Related]
5. Slow-Growing Thalamic Glioma with Histone H3 Lysine 27-to-Methionine Mutation: 3-Year Follow-Up Before Surgical Intervention.
Chanchotisatien A; Pan J; Du Z; Qiu T; Yu J; Chu S
World Neurosurg; 2019 Jul; 127():266-268. PubMed ID: 30981797
[TBL] [Abstract][Full Text] [Related]
6. H3 K27M-mutant diffuse midline gliomas in different anatomical locations.
Wang L; Li Z; Zhang M; Piao Y; Chen L; Liang H; Wei Y; Hu Z; Zhao L; Teng L; Lu D
Hum Pathol; 2018 Aug; 78():89-96. PubMed ID: 29727696
[TBL] [Abstract][Full Text] [Related]
7. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
Karremann M; Gielen GH; Hoffmann M; Wiese M; Colditz N; Warmuth-Metz M; Bison B; Claviez A; van Vuurden DG; von Bueren AO; Gessi M; Kühnle I; Hans VH; Benesch M; Sturm D; Kortmann RD; Waha A; Pietsch T; Kramm CM
Neuro Oncol; 2018 Jan; 20(1):123-131. PubMed ID: 29016894
[TBL] [Abstract][Full Text] [Related]
8. Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience.
Neth BJ; Balakrishnan SN; Carabenciov ID; Uhm JH; Daniels DJ; Kizilbash SH; Ruff MW
J Neurooncol; 2022 Mar; 157(1):91-100. PubMed ID: 35076860
[TBL] [Abstract][Full Text] [Related]
9. Diffuse Midline Gliomas With Histone H3 K27M Mutation in Adults and Children: A Retrospective Series of 164 Cases.
Zheng L; Gong J; Yu T; Zou Y; Zhang M; Nie L; Chen X; Yue Q; Liu Y; Mao Q; Zhou Q; Chen N
Am J Surg Pathol; 2022 Jun; 46(6):863-871. PubMed ID: 35416795
[TBL] [Abstract][Full Text] [Related]
10. Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
Odia Y; Hall MD; Cloughesy TF; Wen PY; Arrillaga-Romany I; Daghistani D; Mehta MP; Tarapore RS; Ramage SC; Allen JE
Neuro Oncol; 2024 May; 26(Supplement_2):S165-S172. PubMed ID: 38386699
[TBL] [Abstract][Full Text] [Related]
11. Tectal Low-Grade Glioma with H3 K27M Mutation.
Sumi K; Shijo K; Igarashi T; Yamamuro S; Sasano M; Oshima H; Ishige T; Honma T; Yagasaki H; Yoshino A
World Neurosurg; 2020 Sep; 141():91-100. PubMed ID: 32505657
[TBL] [Abstract][Full Text] [Related]
12. [Diffuse midline glioma].
Saito R
No Shinkei Geka; 2022 Jan; 50(1):29-38. PubMed ID: 35169084
[TBL] [Abstract][Full Text] [Related]
13. Adult diffuse midline gliomas: Clinical, radiological, and genetic characteristics.
Dono A; Takayasu T; Ballester LY; Esquenazi Y
J Clin Neurosci; 2020 Dec; 82(Pt A):1-8. PubMed ID: 33317715
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of H3 K27M-mutant gliomas in adults.
Meyronet D; Esteban-Mader M; Bonnet C; Joly MO; Uro-Coste E; Amiel-Benouaich A; Forest F; Rousselot-Denis C; Burel-Vandenbos F; Bourg V; Guyotat J; Fenouil T; Jouvet A; Honnorat J; Ducray F
Neuro Oncol; 2017 Aug; 19(8):1127-1134. PubMed ID: 28201752
[TBL] [Abstract][Full Text] [Related]
15. Diffuse hemispheric glioma with H3 p.K28M (K27M) mutation: Unusual non-midline presentation of diffuse midline glioma, H3 K27M-altered?
Donev K; Sundararajan V; Johnson D; Balan J; Chambers M; Paulson VA; Scherpelz KP; Abdullaev Z; Quezado M; Cimino PJ; Pratt D; Valerio E; Alves de Castro JV; Carraro DM; Torrezan GT; Wolff BM; Kulikowski LD; Costa FD; Aldape K; Ida CM
J Neuropathol Exp Neurol; 2024 Apr; 83(5):357-364. PubMed ID: 38447592
[TBL] [Abstract][Full Text] [Related]
16. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
Chi AS; Tarapore RS; Hall MD; Shonka N; Gardner S; Umemura Y; Sumrall A; Khatib Z; Mueller S; Kline C; Zaky W; Khatua S; Weathers SP; Odia Y; Niazi TN; Daghistani D; Cherrick I; Korones D; Karajannis MA; Kong XT; Minturn J; Waanders A; Arillaga-Romany I; Batchelor T; Wen PY; Merdinger K; Schalop L; Stogniew M; Allen JE; Oster W; Mehta MP
J Neurooncol; 2019 Oct; 145(1):97-105. PubMed ID: 31456142
[TBL] [Abstract][Full Text] [Related]
17. Clinicoradiological characteristics of primary spinal cord H3 K27M-mutant diffuse midline glioma.
Cheng L; Wang L; Yao Q; Ma L; Duan W; Guan J; Zhang C; Wang K; Liu Z; Wang X; Wang Z; Wu H; Chen Z; Jian F
J Neurosurg Spine; 2021 Sep; ():1-12. PubMed ID: 34560639
[TBL] [Abstract][Full Text] [Related]
18. A multicenter analysis of the prognostic value of histone H3 K27M mutation in adult high-grade spinal glioma.
Akinduro OO; Garcia DP; Higgins DMO; Vivas-Buitrago T; Jentoft M; Solomon DA; Daniels DJ; Pennington Z; Sherman WJ; Delgardo M; Bydon M; Kalani MA; Zanazzi G; Tsankova N; Bendok BR; McCormick PC; Sciubba DM; Lo SL; Clarke JL; Abode-Iyamah K; Quiñones-Hinojosa A
J Neurosurg Spine; 2021 Aug; 35(6):834-843. PubMed ID: 34416733
[TBL] [Abstract][Full Text] [Related]
19. Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas.
Schreck KC; Ranjan S; Skorupan N; Bettegowda C; Eberhart CG; Ames HM; Holdhoff M
J Neurooncol; 2019 May; 143(1):87-93. PubMed ID: 30864101
[TBL] [Abstract][Full Text] [Related]
20. H3 K27M-mutant diffuse midline glioma with osseous metastases: A case report and a literature review.
Al Sharie S; Talafha M; Abu Laban D; Al Awabdeh T; Al-Mousa A; Al-Masri N; Al-Hussaini M
Clin Neuropathol; 2022; 41(6):263-270. PubMed ID: 35770519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
